摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 1-butyl-5-(4-chlorophenyl)-2-methyl-4-(3-(4-(4-nitrophenyl)piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylate | 1428146-17-1

中文名称
——
中文别名
——
英文名称
tert-butyl 1-butyl-5-(4-chlorophenyl)-2-methyl-4-(3-(4-(4-nitrophenyl)piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylate
英文别名
Tert-butyl 1-butyl-5-(4-chlorophenyl)-2-methyl-4-[3-[4-(4-nitrophenyl)piperazin-1-yl]phenyl]pyrrole-3-carboxylate;tert-butyl 1-butyl-5-(4-chlorophenyl)-2-methyl-4-[3-[4-(4-nitrophenyl)piperazin-1-yl]phenyl]pyrrole-3-carboxylate
tert-butyl 1-butyl-5-(4-chlorophenyl)-2-methyl-4-(3-(4-(4-nitrophenyl)piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylate化学式
CAS
1428146-17-1
化学式
C36H41ClN4O4
mdl
——
分子量
629.199
InChiKey
LXUSMGNDBGBXMB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    747.4±60.0 °C(predicted)
  • 密度:
    1.20±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    8.5
  • 重原子数:
    45
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    83.5
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl 1-butyl-5-(4-chlorophenyl)-2-methyl-4-(3-(4-(4-nitrophenyl)piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylate硫酸 、 palladium 10% on activated carbon 、 氢气 作用下, 以 四氢呋喃甲醇二氯甲烷 为溶剂, 反应 0.42h, 生成
    参考文献:
    名称:
    A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
    摘要:
    Our previously reported Bcl-2/Bcl-xL inhibitor, 4, effectively inhibited tumor growth but failed to achieve complete regression in vivo. We have now performed extensive modifications on its pyrrole core structure, which has culminated in the discovery of 32 (BM-1074). Compound 32 binds to Bcl-2 and Bcl-xL proteins with K-i values of <1 nM and inhibits cancer cell growth with IC50 values of 1-2 nM in four small-cell lung cancer cell lines sensitive to potent and specific Bcl-2/Bcl-xL inhibitors. Compound 32 is capable of achieving rapid, complete, and durable tumor regression in vivo at a well-tolerated dose schedule. Compound 32 is the most potent and efficacious Bcl-2/Bcl-xL inhibitor reported to date.
    DOI:
    10.1021/jm4001105
  • 作为产物:
    参考文献:
    名称:
    A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
    摘要:
    Our previously reported Bcl-2/Bcl-xL inhibitor, 4, effectively inhibited tumor growth but failed to achieve complete regression in vivo. We have now performed extensive modifications on its pyrrole core structure, which has culminated in the discovery of 32 (BM-1074). Compound 32 binds to Bcl-2 and Bcl-xL proteins with K-i values of <1 nM and inhibits cancer cell growth with IC50 values of 1-2 nM in four small-cell lung cancer cell lines sensitive to potent and specific Bcl-2/Bcl-xL inhibitors. Compound 32 is capable of achieving rapid, complete, and durable tumor regression in vivo at a well-tolerated dose schedule. Compound 32 is the most potent and efficacious Bcl-2/Bcl-xL inhibitor reported to date.
    DOI:
    10.1021/jm4001105
点击查看最新优质反应信息

文献信息

  • A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
    作者:Angelo Aguilar、Haibin Zhou、Jianfang Chen、Liu Liu、Longchuan Bai、Donna McEachern、Chao-Yie Yang、Jennifer Meagher、Jeanne Stuckey、Shaomeng Wang
    DOI:10.1021/jm4001105
    日期:2013.4.11
    Our previously reported Bcl-2/Bcl-xL inhibitor, 4, effectively inhibited tumor growth but failed to achieve complete regression in vivo. We have now performed extensive modifications on its pyrrole core structure, which has culminated in the discovery of 32 (BM-1074). Compound 32 binds to Bcl-2 and Bcl-xL proteins with K-i values of <1 nM and inhibits cancer cell growth with IC50 values of 1-2 nM in four small-cell lung cancer cell lines sensitive to potent and specific Bcl-2/Bcl-xL inhibitors. Compound 32 is capable of achieving rapid, complete, and durable tumor regression in vivo at a well-tolerated dose schedule. Compound 32 is the most potent and efficacious Bcl-2/Bcl-xL inhibitor reported to date.
查看更多